Expanding the family of phospholane-based ligands: 1,2-bis(2,5-diphenylphospholano)ethane.

Org Lett

Dowpharma, Chirotech Technology Ltd., a Subsidiary of The Dow Chemical Company, Unit 321, Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, UK.

Published: April 2003

[reaction: see text] 1,2-Bis(2,5-diphenylphospholano)ethane (Ph-BPE) has been synthesized for the first time through employment of an undemanding synthetic pathway. The new ligand exhibits enhanced activity and selectivity over the existing members of the BPE ligand family in rhodium-catalyzed asymmetric hydrogenation.

Download full-text PDF

Source
http://dx.doi.org/10.1021/ol0341952DOI Listing

Publication Analysis

Top Keywords

expanding family
4
family phospholane-based
4
phospholane-based ligands
4
ligands 12-bis25-diphenylphospholanoethane
4
12-bis25-diphenylphospholanoethane [reaction
4
[reaction text]
4
text] 12-bis25-diphenylphospholanoethane
4
12-bis25-diphenylphospholanoethane ph-bpe
4
ph-bpe synthesized
4
synthesized time
4

Similar Publications

The family of PEComa encompasses a heterogeneous group of related mesenchymal neoplasms with myomelanocytic differentiation, a distinctive subset of which is characterized by TFE3 gene rearrangement. Recurrent YAP1::TFE3 fusion has been found in clear cell stromal tumor of the lung (CCST-L), and most recently, in two cases classified as inflammatory spindle cell PEComa. However, the potential relationship between CCST-L and PEComa remains unclear.

View Article and Find Full Text PDF

Background: Our current understanding of the molecular mechanisms underlying amyloidogenesis in Alzheimer's Disease (AD) is limited by the lack of comprehensive models closely resembling human pathology. Human induced pluripotent stem cell (hiPSC) 3-dimensional (3D) models, such as brain organoids and neurospheres, are emerging as innovative approaches to model neurodegenerative diseases in vitro. However, they rely on hiPSC self-organization and are therefore characterized by low reproducibility and homogeneity.

View Article and Find Full Text PDF

Background: We researched the occurrence, neuropathology, and clinical features of spastic paraplegia (SP) associated to dementia in presenilin 1 (PSEN1) Italian patients related to familial Alzheimer's disease (AD).

Methods: We carried out whole exome sequencing in 33 familial AD probands with hereditary spastic paraplegia (HSP) that resulted negative for the identification of pathogenetic variants in known HSP genes. One patient was identified with a DNA variant in PSEN1, and bioinformatic analysis was conducted to characterize its pathogenetic nature.

View Article and Find Full Text PDF

Development of a Breastfeeding and Lactation Medicine Division Over a Seven-Year Period: An Homage to Dr Ruth A. Lawrence.

Breastfeed Med

January 2025

Divisions of Breastfeeding and Lactation Medicine and Allergy Immunology, Department of Pediatrics, University of Rochester, Rochester, New York, USA.

Breastfeeding and Lactation Medicine (BFLM) programs at academic medical centers are uncommon but expanding. Our academic medical center, with a long legacy of leadership in BFLM, established a BFLM program in 2016 and launched a dedicated division in 2022. To describe the strategy, services, measures, and challenges facing our multidisciplinary academic BFLM program in its first 8 years.

View Article and Find Full Text PDF

Clinical Manifestations.

Alzheimers Dement

December 2024

Memory and Aging Center, UCSF Weill Institute for Neurosciences, San Francisco, CA, USA.

Background: The ALLFTD (ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration) study is an NIH-funded effort to prepare for clinical trials in sporadic (s-FTLD) and familial (f-FTLD) FTLD syndromes by characterizing cohorts, developing new clinical trial outcome measures, and evaluating disease progression. To understand disease trajectories in the context of potential preventative or disease-modifying therapeutic agents, comprehensive evaluation across multiple time-points is crucial.

Method: ALLFTD evaluates participants with FTLD spectrum disorders (bvFTD, svPPA, nfvPPA, FTD-ALS, CBS, PSP), with strong family histories of FTLD, or known FTLD-associated genetic variants within the family.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!